Literature DB >> 24743516

The complex landscape of pancreatic cancer metabolism.

Cristovão Marques Sousa1, Alec C Kimmelman2.   

Abstract

Pancreatic ductal adenocarcinomas (PDA) are extremely aggressive cancers and currently available therapies are only minimally effective in treating this disease. Tackling this devastating cancer has been a major challenge to the scientific and medical communities, in part due to its intense therapeutic resistance. One of the aspects of this tumor that contributes to its aggressive behavior is its altered cellular metabolism. Indeed, PDA cells seem to possess the ability to adapt their metabolism to the particular environment to which they are exposed, including utilizing diverse fuel sources depending on their availability. Moreover, PDA tumors are efficient at recycling various metabolic substrates through activation of different salvage pathways such as autophagy and macropinocytosis. Together, these diverse metabolic adaptations allow PDA cells to survive and thrive in harsh environments that may lack nutrients and oxygen. Not surprisingly, given its central role in the pathogenesis of this tumor, oncogenic Kras plays a critical role in much of the metabolic reprogramming seen in PDA. In this review, we discuss the metabolic landscape of PDA tumors, including the molecular underpinnings of the key regulatory nodes, and describe how such pathways can be exploited for future diagnostic and therapeutic approaches.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743516      PMCID: PMC4076815          DOI: 10.1093/carcin/bgu097

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  183 in total

Review 1.  Reactive oxygen species: the achilles' heel of cancer cells?

Authors:  Xiaojiang Cui
Journal:  Antioxid Redox Signal       Date:  2012-03-02       Impact factor: 8.401

Review 2.  Reactive oxygen species in cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Free Radic Res       Date:  2010-05

Review 3.  Reactive oxygen species in tumor progression.

Authors:  Peter Storz
Journal:  Front Biosci       Date:  2005-05-01

Review 4.  Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.

Authors:  Jessie Yanxiang Guo; Eileen White
Journal:  Autophagy       Date:  2013-08-15       Impact factor: 16.016

5.  Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin.

Authors:  Jennifer L Illuzzi; Cassie A Vickers; Eric B Kmiec
Journal:  J Mol Neurosci       Date:  2011-04-05       Impact factor: 3.444

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Authors:  Minoru Oshima; Keiichi Okano; Shinobu Muraki; Reiji Haba; Takashi Maeba; Yasuyuki Suzuki; Shinichi Yachida
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism.

Authors:  Jian Chen; Songji Zhao; Kunihiro Nakada; Yuji Kuge; Nagara Tamaki; Futoshi Okada; Jingxin Wang; Masanobu Shindo; Fumihiro Higashino; Kohji Takeda; Masahiro Asaka; Hiroyuki Katoh; Toshio Sugiyama; Masuo Hosokawa; Masanobu Kobayashi
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 9.  Nuclear factor-κB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect.

Authors:  Renée F Johnson; Neil D Perkins
Journal:  Trends Biochem Sci       Date:  2012-05-23       Impact factor: 13.807

10.  LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.

Authors:  Jennifer P Morton; Nigel B Jamieson; Saadia A Karim; Dimitris Athineos; Rachel A Ridgway; Colin Nixon; Colin J McKay; Ross Carter; Valerie G Brunton; Margaret C Frame; Alan Ashworth; Karin A Oien; T R Jeffry Evans; Owen J Sansom
Journal:  Gastroenterology       Date:  2010-05-06       Impact factor: 22.682

View more
  52 in total

1.  Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

Authors:  Nikita S Sharma; Vineet K Gupta; Vanessa T Garrido; Roey Hadad; Brittany C Durden; Kousik Kesh; Bhuwan Giri; Anthony Ferrantella; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.

Authors:  Sandrina Maertin; Jason M Elperin; Ethan Lotshaw; Matthias Sendler; Steven D Speakman; Kazuki Takakura; Benjamin M Reicher; Olga A Mareninova; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-07-13       Impact factor: 4.052

3.  Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.

Authors:  Chen Yuan; Clary B Clish; Chen Wu; Jared R Mayers; Peter Kraft; Mary K Townsend; Mingfeng Zhang; Shelley S Tworoger; Ying Bao; Zhi Rong Qian; Douglas A Rubinson; Kimmie Ng; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Jing Ma; Howard D Sesso; Garnet L Anderson; Barbara B Cochrane; JoAnn E Manson; Margaret E Torrence; Alec C Kimmelman; Laufey T Amundadottir; Matthew G Vander Heiden; Charles S Fuchs; Brian M Wolpin
Journal:  J Natl Cancer Inst       Date:  2016-01-11       Impact factor: 13.506

Review 4.  The Intricate Metabolism of Pancreatic Cancers.

Authors:  Felipe Camelo; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 5.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

6.  Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.

Authors:  Suman Mukhopadhyay; Debanjan Goswami; Pavan P Adiseshaiah; William Burgan; Ming Yi; Theresa M Guerin; Serguei V Kozlov; Dwight V Nissley; Frank McCormick
Journal:  Cancer Res       Date:  2020-01-07       Impact factor: 12.701

7.  p38 MAPK in pancreatic cancer: finding a protective needle in the haystack.

Authors:  Murray Korc
Journal:  Clin Cancer Res       Date:  2014-08-18       Impact factor: 12.531

Review 8.  Pancreatic cancer biology and genetics from an evolutionary perspective.

Authors:  Alvin Makohon-Moore; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Cancer       Date:  2016-07-22       Impact factor: 60.716

Review 9.  Molecular therapeutics in pancreas cancer.

Authors:  Vignesh Narayanan; Colin D Weekes
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

10.  Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.

Authors:  Xunhao Xiong; Geeta Rao; Ram Vinod Roy; Yushan Zhang; Nicolas Means; Anindya Dey; Martha Tsaliki; Sounik Saha; Sanjib Bhattacharyya; Shailendra Kumar Dhar Dwivedi; Chinthalapally V Rao; Daniel J McCormick; Danny Dhanasekaran; Kai Ding; Elizabeth Gillies; Min Zhang; Da Yang; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  FASEB J       Date:  2020-07-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.